nach oben

International Journal of Clinical Oncology

Erschienen in:

01.04.2019 | Original Article

Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer

verfasst von: Shuji Hiramoto, Tomoko Tamaki, Kengo Nagashima, Tetsuo Hori, Ayako Kikuchi, Akira Yoshioka, Akira Inoue

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear.

Method

Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of chemotherapy. The secondary endpoint was to analyze the relationship between EOL symptoms and EOL treatment details.

Results

Among 300 evaluated patients, the number of patients who died within 14 and 30 days from the last administration of chemotherapy were 16 (5.3%) and 50 (16.7%), respectively. Multivariate analysis revealed that ECOG-PS (OR 3.698, p < 0.001) and GPS2 (OR 3.791, p = 0.028) were significant prognostic factors. The MST of patients with both PS 2–4 and GPS2 (+) was 38 days, while that in patients with both PS 0–1 and GPS2 (−) was 134.5 days. The prevalence rate of nausea and vomiting (25.0%) and the mean hydration volume (0.50 L/day) in patients who died within 30 days from the chemotherapy was significantly higher than others (7.4%) (0.20 L/day).

Conclusion

ECOG-PS and GPS were significant prognostic factors for aggressive EOL chemotherapy. Information on these factors may aid clinical decision-making in terms of risk–benefit balance, particularly in patients with poor prognosis.

Nur mit Berechtigung zugänglich

Earle CC, Neville BA, Lndrum MB et al (2004) Trends in aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321CrossRefPubMed

Nappa U, Lindqvist O, Rasmussen BA et al (2011) Palliative chemotherapy during the last month of life. Ann Oncol 22:2375–2380CrossRefPubMed

Braga S, Rute Fonseca AM, Moreira A et al (2007) The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Pscho-Oncology 16:863–868CrossRef

Barbera L (2006) Indicators of poor quality end-of-life cancer care in Ontario. J Palliat Care 22:12–17PubMedCrossRef

Hanny A, Sonja H, Georg B (2014) Chemotherapy near the end of life: a retrospective single-centere analysis of patients’ charts. BMC Palliat Care 13:26CrossRef

Kao S, Shafig J, Adams D (2009) Use of chemotherapy at end of life in oncology patients. Ann Oncol 20:1555–1559CrossRefPubMed

Petra G, Aynharan S, Theresas T et al (2015) Variations in intensity of end-of-life cancer therapy by cancer type at a Canadian tertiary cancer centre between 2003 and 2010. Support Care Cancer 23(10):3059–67CrossRef

Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030CrossRefPubMedPubMedCentral

Inoue SK, van Dyck CH, Alessi CA et al (1990) Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 113:941–948CrossRef

10.

Morita T, Bito S, Kurihara Y et al (2005) Development of a clinical guideline for palliative sedation therapy using the Delphi method. J Palliat Med 8:716–729CrossRefPubMed

11.

Prigerson HG, Bao Y, Shah M et al (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1(6):778–784CrossRefPubMedPubMedCentral

12.

Nozoe T, Ninomiya M, Maeda T et al (2010) Prognostic nutritional index: a tool to predict the biological aggressivenesss of gastric carcinoma. Surg Today 40:440–443CrossRefPubMed

13.

Maeda K, Shibutani M, Otani H et al (2014) Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor. Eorld J Surg 38:1217–1222

14.

Kanda M, Fujii T, Kodera Y et al (2011) Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98:268–274CrossRefPubMed

15.

Masaichi O, Naoshi K, Go M et al (2015) Glasgow prognostic score as a prognostic clinical marker in T4 esophageal squamous cell carcinoma. Anticancer Res 35:4897–4902

16.

Okuno T, Wakabayashi M, Kato K et al (2017) Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). Int J Clin Oncol 22(6):1042–1049CrossRefPubMedPubMedCentral

17.

Hiramoto S, Kato K, Boku N (2018) A retrospective analysis of 5-fluorouracil plus cisplatin as first line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Int J Clin Oncol 23(3):466–472CrossRefPubMed

18.

Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27(9):1394–1400CrossRefPubMed

Titel: Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer
verfasst von: Shuji Hiramoto
Tomoko Tamaki
Kengo Nagashima
Tetsuo Hori
Ayako Kikuchi
Akira Yoshioka
Akira Inoue
Publikationsdatum: 01.04.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 4/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1363-7

Springer Medizin

Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer